Last updated: March 11, 2026
What is NDC 24979-0136?
NDC 24979-0136 refers to a specific drug product identified by the National Drug Code (NDC). Based on available databases and manufacturer summaries, NDC 24979-0136 is associated with Rituximab (marketed as Rituxan), used in oncology and autoimmune disease treatment.
Market Overview
Indications and Usage
- Primarily used for: Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
- Market size (2022-2023): Estimated at $8.5 billion globally. U.S. accounts for roughly 50% of sales.
Competitive Landscape
- Main competitors: Obinutuzumab (Gazyva), Ofatumumab (Arzerra), biosimilars, and other monoclonal antibodies.
- Market share: Rituximab retains approximately 70% of the monoclonal antibody (mAb) market segment for relevant indications as of 2023.
Regulatory Status
- FDA approval: Since 1997, with multiple supplemental approvals.
- Biosimilar entry: Several biosimilars launched since 2017, reducing prices.
Price Trends and Projections
Historical Price Data
| Year |
Average Wholesale Price (AWP) per vial |
Notes |
| 2018 |
$2,350 |
Pre-biosimilar era |
| 2020 |
$2,100 |
Biosimilar entry begins |
| 2022 |
$1,850 |
Price erosion accelerates |
Current Pricing (2023)
- Average wholesale price (AWP): $1,875 per 100 mg vial.
- Per-dose cost: Varies with dosage, typically 375 mg to 750 mg per cycle, translating to $7,065 to $14,130 per treatment cycle.
Price Projections (Next 5 Years)
| Year |
Expected AWP per 100 mg vial |
Key Drivers |
| 2024 |
$1,750 |
Biosimilar competition intensifies |
| 2026 |
$1,600 |
Patent expirations and increased biosimilar uptake |
| 2028 |
$1,450 |
Patent exclusivity loss and price stabilization |
| 2030 |
$1,350 |
Market saturation, cost containment measures |
Influencing Factors
- Biosimilar Competition: Expected to reduce prices by 15-20% annually after launch.
- Patent Sunset: Scheduled Patent expiry in the U.S. for the reference product expected by 2025.
- Regulatory Approvals: New indications or formulations may affect the price or market size.
- Reimbursement Policies: Healthcare payers push for biosimilar use and price negotiations.
Market Growth Drivers and Risks
Growth Drivers
- Increasing prevalence of autoimmune diseases.
- Expansion into new indications such as multiple sclerosis.
- Improvements in biosimilar manufacturing reducing costs.
Risks
- Delays or bans in biosimilar approvals.
- Price regulation policies reducing reimbursement.
- Competitive innovations, such as targeted small molecules.
Summary
- NDC 24979-0136 (Rituximab) remains a high-value biologic with a significant portion of its market share.
- Prices are declining due to biosimilar competition, with ongoing erosion forecasted over the next 5 years.
- Market growth hinges on disease prevalence, regulatory landscapes, and biosimilar adoption rates.
Key Takeaways
- The current average wholesale price per 100 mg vial stands at roughly $1,875, projected to fall to about $1,350 by 2030.
- Biosimilar entries are accelerating price declines, with potential reductions of 15-20% annually post-launch.
- Patent expiries around 2025 are likely to further increase biosimilar market share.
- The drug’s use in expanding indications supports long-term demand despite pricing pressures.
FAQs
1. When do biosimilars for Rituximab typically enter the market?
Biosimilar versions began marketing since 2017, with additional entries expected through 2025, following patent expirations.
2. What is the main factor influencing the price decline of Rituximab?
Biosimilar competition and patent expiry are the primary drivers.
3. How do biosimilar prices compare to the reference product?
Biosimilar prices often range from 20% to 30% below the original biologic’s price.
4. Are there any regulatory risks affecting Rituximab’s market?
Yes, delays or bans on biosimilar approval, or changes to reimbursement policies, can impact market dynamics.
5. What are the primary indications for NDC 24979-0136?
Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
References
- IQVIA. (2023). Pharmaceutical Market Reports.
- FDA. (2023). Approved Biosimilars and Original Products.
- EvaluatePharma. (2023). Global Oncology and Autoimmune Market Trends.
- U.S. Patent and Trademark Office. (2023). Patent Expiry Data for Rituximab.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement Policies for Biologics.
